Blood products company, CSL Limited (ASX: CSL) has today reported a full year net profit of $983m, up 4.5% over the previous year. In constant currency terms, profit was up 16%, but the strong Australian dollar reduced the profit by $108m.
Sales revenues were up 7%, while earnings per share was up 9% to $1.89, thanks to the company’s ongoing share buyback, which CSL has suggested maybe increased by a further $900m, once the current program has been completed. The company still has around $207m left of its existing buyback. In the last three years, CSL has spent more than $3 billion buying back shares.
Research and development expenditure rose 13% in constant currency terms, to $355m, as CSL continues to invest in future blood plasma products. Its existing business appears to be doing exceptionally well, with sales of Immunoglobin and Albumin both up 15% and speciality products up 18%.
With a number of other products in its pipeline, either under development or undergoing trials, CSL looks well placed to generate growth over the next few years. In fact, the company expects profits to grow at 12% using current exchange rates. Any fall in the value of the Australian dollar against the US dollar, is likely to raise that growth rate.
CSL is regarded as one of Australia’s world beating companies, alongside Cochlear Limited (ASX: COH), Computershare (ASX: CPU), Aristocrat Leisure Limited (ASX: ALL) and BHP Billiton Limited (ASX: BHP) to name but a few. These companies are market leaders in their respective fields, with large market shares and competitive advantages that make it difficult for competitors to knock them down.
Today’s result confirms that CSL is still standing tall and appears to have a continuing strong future ahead of it.
The Foolish bottom line
CSL trades on a P/E ratio of over 22 at the current price of $42.39, and although it shares look expensive, the company continues to deliver attractive results.
If you’re in the market for some high yielding ASX shares, look no further than our “Secure Your Future with 3 Rock-Solid Dividend Stocks” report. In this free report, we’ve put together our best ideas for investors who are looking for solid companies with high dividends and good growth potential. Click here now to find out the names of our three favourite income ideas. But hurry – the report is free for only a limited time.
- Who said the mining boom was dead?
- Arrium: That’s not a turnaround
- Sydney Airport continues to fly high
- Busting the myth of innovation at Google
Motley Fool writer/analyst Mike King owns shares in CSL, Cochlear and BHP. The Motley Fool‘s purpose is to help the world invest, better. Take Stock is The Motley Fool’s free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. Click here now to request your free subscription, whilst it’s still available. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.
These 3 stocks could be the next big movers in 2020
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
In this FREE STOCK REPORT, Scott just revealed what he believes are the 3 ASX stocks for the post COVID world that investors should buy right now while they still can. These stocks are trading at dirt-cheap prices and Scott thinks these could really go gangbusters as we move into ‘the new normal’.
*Returns as of 6/8/2020
- Why PWR Holdings Ltd could see its share price rise from here – July 21, 2017 12:11pm
- Fortescue Metals Group Limited share price sinks on native title decision – July 20, 2017 4:23pm
- 5 overlooked finance shares to add to your watchlist – July 20, 2017 2:33pm